Literature DB >> 20668443

Anti-(+)-methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addiction.

W B Gentry1, D Rüedi-Bettschen, S M Owens.   

Abstract

Anti-(+)-methamphetamine monoclonal antibodies (mAbs) have the potential to reduce the devastating behavioral and societal effects of the worldwide epidemic of (+)-methamphetamine (METH) addiction and transform the treatment paradigm for diseases of addiction. These novel, protein-based medications could play a vital role in helping patients to achieve sustainable abstinence from METH abuse by serving as an in vivo, around-the-clock sentry against a patient's vulnerability to relapse.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20668443      PMCID： PMC3652404          DOI： 10.1038/clpt.2010.155

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  20 in total

Review 1.  Some relationships between addiction and drug delivery to the brain.

Authors:  W H Oldendorf
Journal:  NIDA Res Monogr       Date:  1992

2.  The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse.

Authors:  F Ivy Carroll; Philip Abraham; Paul K Gong; Ramakrishna R Pidaparthi; Bruce E Blough; Yingni Che; Amber Hampton; Melinda Gunnell; Jackson O Lay; Eric C Peterson; S Michael Owens
Journal:  J Med Chem       Date:  2009-11-26       Impact factor: 7.446

3.  Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats.

Authors:  Kelly A Byrnes-Blake; Elizabeth M Laurenzana; Reid D Landes; W Brooks Gentry; S Michael Owens
Journal:  Eur J Pharmacol       Date:  2005-09-21       Impact factor: 4.432

4.  Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted.

Authors:  Grzegorz Pitas; Elizabeth M Laurenzana; D Keith Williams; S Michael Owens; W Brooks Gentry
Journal:  Drug Metab Dispos       Date:  2006-02-28       Impact factor: 3.922

5.  Rate of increase of plasma drug level influences subjective response in humans.

Authors:  H de Wit; B Bodker; J Ambre
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  Inhibition of nicotine-induced seizures in rats by combining vaccination against nicotine with chronic nicotine infusion.

Authors:  Y Tuncok; Y Hieda; D E Keyler; S Brown; S Ennifar; A Fattom; P R Pentel
Journal:  Exp Clin Psychopharmacol       Date:  2001-05       Impact factor: 3.157

7.  Differential effects of passive immunization with nicotine-specific antibodies on the acute and chronic distribution of nicotine to brain in rats.

Authors:  P R Pentel; M B Dufek; S A Roiko; M G Lesage; D E Keyler
Journal:  J Pharmacol Exp Ther       Date:  2006-01-11       Impact factor: 4.030

8.  Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats.

Authors:  Elizabeth M Laurenzana; Kelly A Byrnes-Blake; Alessandra Milesi-Hallé; W Brooks Gentry; D Keith Williams; S Michael Owens
Journal:  Drug Metab Dispos       Date:  2003-11       Impact factor: 3.922

9.  Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody.

Authors:  H Marie Lacy; Melinda G Gunnell; Elizabeth M Laurenzana; S Michael Owens
Journal:  Int Immunopharmacol       Date:  2007-10-23       Impact factor: 4.932

10.  Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats.

Authors:  Elizabeth M Laurenzana; Howard P Hendrickson; Dylan Carpenter; Eric C Peterson; W Brooks Gentry; Michael West; Yingni Che; F Ivy Carroll; S Michael Owens
Journal:  Vaccine       Date:  2009-10-01       Impact factor: 3.641
View more
  16 in total

Review 1.  Pharmacokinetic strategies for treatment of drug overdose and addiction.

Authors:  David A Gorelick
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

2.  Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response.

Authors:  Michael D Hambuchen; F Ivy Carroll; Daniela Rüedi-Bettschen; Howard P Hendrickson; Leah J Hennings; Bruce E Blough; Lawrence E Brieaddy; Ramakrishna R Pidaparthi; S Michael Owens
Journal:  J Med Chem       Date:  2015-05-22       Impact factor: 7.446

Review 3.  Future pharmacological treatments for substance use disorders.

Authors:  Ariadna Forray; Mehmet Sofuoglu
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

4.  Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period.

Authors:  Michael D Hambuchen; Daniela Rüedi-Bettschen; D Keith Williams; Howard Hendrickson; S Michael Owens
Journal:  Vaccine       Date:  2014-09-22       Impact factor: 3.641

5.  In silico experiments of single-chain antibody fragment against drugs of abuse.

Authors:  Guodong Hu; L Y Chen
Journal:  Biophys Chem       Date:  2010-10-18       Impact factor: 2.352

6.  Synthesis of mercapto-(+)-methamphetamine haptens and their use for obtaining improved epitope density on (+)-methamphetamine conjugate vaccines.

Authors:  F Ivy Carroll; Bruce E Blough; Ramakrishna R Pidaparthi; Philip Abraham; Paul K Gong; Liu Deng; Xiaodong Huang; Melinda Gunnell; Jackson O Lay; Eric C Peterson; S Michael Owens
Journal:  J Med Chem       Date:  2011-06-29       Impact factor: 7.446

7.  Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food.

Authors:  Daniela Rüedi-Bettschen; Sherri L Wood; Melinda G Gunnell; C Michael West; Rama R Pidaparthi; F Ivy Carroll; Bruce E Blough; S Michael Owens
Journal:  Vaccine       Date:  2013-07-29       Impact factor: 3.641

Review 8.  Customizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applications.

Authors:  Eric C Peterson; W Brooks Gentry; S Michael Owens
Journal:  Adv Pharmacol       Date:  2014

Review 9.  Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction.

Authors:  S Michael Owens; William T Atchley; Michael D Hambuchen; Eric C Peterson; W Brooks Gentry
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-12       Impact factor: 4.388

10.  Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development.

Authors:  Elizabeth M Laurenzana; Misty W Stevens; John C Frank; Michael D Hambuchen; Howard P Hendrickson; Sarah J White; D Keith Williams; S Michael Owens; W Brooks Gentry
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.